Compare OSIP to:
Real-Time: 33.90 -0.28 (-0.82%) 11:41am ET
| Last Trade: | 33.97 |
|---|---|
| Trade Time: | 11:25am ET |
| Change: | |
| Prev Close: | 34.18 |
| Open: | 34.52 |
| Bid: | 33.97 x 300 |
| Ask: | 34.00 x 200 |
| 1y Target Est: | 38.60 |
| Day's Range: | 33.76 - 34.52 |
|---|---|
| 52wk Range: | 27.01 - 42.44 |
| Volume: | 142,617 |
| Avg Vol (3m): | 871,535 |
| Market Cap: | 1.97B |
| P/E (ttm): | 5.24 |
| EPS (ttm): | 6.49 |
| Div & Yield: | N/A (N/A) |
| Tue 4:45pm | [$$] Rob's Wrap: OSIP, FXP, VSH, SLEat RealMoney by TheStreet.com |
| Tue 10:00am | OSI Pharmaceuticals to Announce Fourth Quarter and Year-End 2009 Financial Results on February 23, 2010Business Wire |
| Thu, Jan 28 | Novella Clinical and OSI Pharmaceuticals Expand Clinical Services AgreementBusiness Wire |
| Wed, Jan 27 | 67% Decline In Consumable Cost For Human Genome Sequencing Seen In 2010 By First Analysis Equity Valuation ExpertWall Street Transcript |
| Fri, Jan 22 | Pfizer's Great Data Won't Do Muchat Motley Fool |
| Wed, Jan 20 | Today's 5-Star Moversat Motley Fool |
| Tue, Jan 19 | OSI PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online |
| Fri, Jan 15 | UPDATE - OSI Pharma says FDA extends Tarceva reviewat Reuters |
| Fri, Jan 15 | FDA Extends Review Period for Tarceva Application for First-Line Maintenance Use in Advanced Non-Small Cell Lung CancerBusiness Wire |
| Tue, Jan 12 | OSI reports 17 percent boost in Tarceva salesAP |
Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for NASDAQ, NYSE and Amex.See also delay times for other exchanges.